14
Participants
Start Date
April 28, 2022
Primary Completion Date
November 22, 2022
Study Completion Date
November 22, 2022
Ganaplacide
Period 1: 400 mg (4 x 100 mg tablets) for oral administration Period 2: 400 mg (4 x 100 mg tablets) for oral administration
Lumefantrine
Period 1: 480 mg (2 x 240 mg sachets) for oral administration Period 2: 480 mg (2 x 240 mg sachets) for oral administration
Efavirenz
Period 2: 600 mg (1 x 600 mg tablet) for oral administration once daily (q.d.)
Novartis Investigative Site, Belfast
Lead Sponsor
Medicines for Malaria Venture
OTHER
Novartis Pharmaceuticals
INDUSTRY